Collectively, these results suggest that therapeutically targeting or manipulating the GITR-GITRL pathway provides strong rationale for unique approaches to cancer immunotherapy and for their potential combination with other TNFR agonists (e.g. CD137, OX40) [46–47]. This evidence concerns the gene TNFRSF9 and cancer.